Product Description: Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor. Lomedeucitinib has anti-inflammatory activity and significant inhibitory effect on IFNα (IC50=0.047 μM) production downstream of IL-12/TYK2. Lomedeucitinib is indicated for the study of plaque psoriasis and pruritus[1][2][3].
Applications: COVID-19-immunoregulation
Formula: C18H17D3N6O4S
References: [1]Drakos A, et al. Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents[J]. Pharmaceutics, 2024, 16(1): 111./[2]Zhang K, et al. Development and therapeutic implications of tyrosine kinase 2 inhibitors[J]. Journal of Medicinal Chemistry, 2023, 66(7): 4378-4416./[3]Andrew Nicholas Billin, et al. Il-31 modulators for treating fxr-induced pruritis. WO2022266444A1. 2022-06-17
CAS Number: 2328068-29-5
Molecular Weight: 419.47
Compound Purity: 99.75
Research Area: Inflammation/Immunology
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: IFNAR;Isotope-Labeled Compounds;JAK
English
Deutsch
